The verdict
Our read at a glance.
Whether hexarelin's ability to raise growth hormone in older studies supports the muscle, recovery, and anti-aging claims made for it today.
- The signal
- Older human studies show hexarelin raises growth hormone, and some research looked at heart and vascular effects. There is little modern clinical development, and it is not approved for any use. Evidence for the muscle, recovery, and anti-aging claims is limited.
- The unknown
- Whether raising growth hormone with hexarelin produces meaningful benefits, whether tolerance to its growth-hormone effect develops, and how its older research applies to current gray-market products.
- Our read
- An old GH-releasing peptide with thin, dated evidence, not a proven therapy. Hexarelin does raise growth hormone, but there is little modern clinical development and no approval, so its muscle and anti-aging claims rest on weak ground.
The mechanism
How it works.
Hexarelin is a synthetic six-amino-acid peptide that acts like the hormone ghrelin. It binds the ghrelin receptor (GHSR) in the pituitary and triggers a pulse of growth hormone release, which is the basis for its use in older studies of the GH axis. Some research also explored whether it acts directly on heart tissue, but that work is dated, and its GH-raising effect alone does not establish the muscle, recovery, or anti-aging claims made for it.
Safety & regulatory boundary
The consequential part.
Hexarelin is not an approved drug and is sold as a research chemical, where product identity and quality are uncertain. Its growth-hormone and cardiovascular effects are not free of risk, and its older research does not validate modern muscle, recovery, or anti-aging claims. It should not be treated as an approved or proven therapy.
What's next
What we're watching.
Any modern controlled trials, regulatory actions on gray-market GHRPs, and long-term safety data.
Context
Why this is discussed.
Hexarelin is one of the classic GH-releasing peptides discussed in the performance and anti-aging communities, alongside GHRP-6 and GHRP-2.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Kolovou GD et al. · Biomed Res Int · 2014
Mao Y et al. · J Geriatr Cardiol · 2014
Sigalos JT et al. · Sex Med Rev · 2018
Ghigo E et al. · Eur J Endocrinol · 1997
Mosa RM et al. · Endocrine · 2015
Maréchal L et al. · Int J Mol Sci · 2018
Scacchi M et al. · Int J Obes Relat Metab Disord · 1999
Colao A et al. · Clin Endocrinol (Oxf) · 2001
Camanni F et al. · Front Neuroendocrinol · 1998
Coiro V et al. · J Intern Med · 2000
Bisi G et al. · J Endocrinol Invest · 1999
Muccioli G et al. · Ann Endocrinol (Paris) · 2000
Keep reading